Synagis Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Palivizumab

Indications/Uses

Prevention of serious lower resp tract disease caused by resp syncytial virus (RSV) in childn at high risk of RSV disease.

Click to view Synagis detailed prescribing information

Dosage/Direction for Use

15 mg/kg IM once mthly, 1st dose to be given prior to RSV season & subsequent doses to be given mthly throughout RSV season. Childn who receive palivizumab & become infected w/ RSV Continue receiving mthly doses of palivizumab for the duration of RSV season.

Click to view Synagis detailed prescribing information

Overdosage

View Synagis overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity to palivizumab or other humanized monoclonal Ab.

Click to view Synagis detailed prescribing information

Special Precautions

Discontinue use if severe hypersensitivity reaction occurs. Thrombocytopenia or any coagulation disorder. Moderate to severe acute infection or febrile illness. Pregnancy & lactation.

Click to view Synagis detailed prescribing information

Use In Pregnancy & Lactation

Click to view Synagis detailed prescribing information

Adverse Reactions

Rash; pyrexia. Inj site reaction.

Click to view Synagis detailed prescribing information

Drug Interactions

May interfere w/ immune-based RSV diagnostic tests eg, some antigen detection-based assays; viral culture assays.

Click to view Synagis detailed prescribing information

Storage

View Synagis storage conditions for details to ensure optimal shelf-life.

Description

View Synagis description for details of the chemical structure and excipients (inactive components).

Action

View Synagis mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J06BD01 - palivizumab ; Belongs to the class of antiviral monoclonal antibodies. Used in passive immunizations.

Regulatory Classification

Presentation/Packing

Form

Synagis soln for inj 100 mg/mL

Packing/Price

1's

Synagis

palivizumab

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma